

SENTARA HEALTH PLANS

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-668-1550**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed.**

For Medicare Members: Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Drug Requested: Soliris® (eculizumab) IV (J1299) (Medical)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

Recommended Dosage:

- **Maximum Quantity Limit – 4 vials every 14 days; one 300 mg vial (30 mL) = 150 billable units [1 billable unit per 2 mg]**
 - IV Induction – 600 mg weekly for 4 doses
 - Maintenance – 900 mg at week 5, then 900 mg every 2 weeks thereafter

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- ☐ Medication must be prescribed by or in consultation with a hematologist or nephrologist
- ☐ Prescriber must be enrolled in the Soliris® Risk Evaluation and Mitigation Strategy (REMS) program
- ☐ Member must be 18 years of age or older
- ☐ Member must have a diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) confirmed by detection of PNH clones of at least 10% by flow cytometry testing (**must submit labs**)
- ☐ Flow cytometry pathology report must demonstrate at least 2 different glycosylphosphatidylinositol (GPI) protein deficiencies (e.g., CD55, CD59, etc.) within 2 different cell lines from granulocytes, monocytes, erythrocytes (must submit labs)
- ☐ Member must have **ONE** of the following indications for therapy (**must submit chart notes and labs**):
 - ☐ Member is transfusion dependent as defined by having a transfusion within the last 12 months and **ONE** of the following:
 - ☐ Member's hemoglobin is less than or equal to 7 g/dL
 - ☐ Member has symptoms of anemia and the hemoglobin is less than or equal to 9 g/dL
 - ☐ Member has high lactate dehydrogenase (LDH) level (defined as ≥ 1.5 times the upper limit of the normal range with clinical symptoms)
 - ☐ Presence of a thrombotic event (e.g., DVT, PE)
 - ☐ Presence of organ damage secondary to chronic hemolysis
 - ☐ Presence of organ damage secondary to chronic hemolysis
 - ☐ Member is pregnant and potential benefit outweighs potential fetal risk
- ☐ Member does **NOT** have a systemic infection
- ☐ Member must be administered a meningococcal vaccine **at least two weeks prior** to initiation of Soliris® therapy and revaccinated according to current medical guidelines for vaccine use
- ☐ Member has **NOT** received a meningococcal vaccination **at least two weeks prior** to the initiation of therapy with Soliris® and documented the risks of delaying Soliris® therapy outweigh the risks of developing a meningococcal infection
- ☐ Medication will **NOT** be prescribed concurrently with another FDA approved product prescribed for treatment of PNH (e.g., Bkempv™, Epsysqli™, PiaSky®, Ultomiris®, Empaveli®, or Fabhalta®)

Reauthorization: 6 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Member continues to meet all initial authorization criteria

(Continued on next page)

- ☐ Provider attests to an absence of unacceptable toxicity from the drug (e.g., serious meningococcal infections (septicemia and/or meningitis), infusion reactions, serious infections)
- ☐ Member has experienced positive disease response indicated by at least **ONE** of the following (**check all that apply; results must be submitted to document improvement**):
 - ☐ Documentation of a recent (within 3 months) LDH level that shows a reduction from baseline
 - ☐ Documentation that the member has stabilized hemoglobin levels as supported by **ONE** of the following:
 - ☐ Member had a reduction in number of transfusions **OR** units of packed red cells transfused from baseline
 - ☐ Member maintained a hemoglobin concentration above 7 g/dL **OR** maintained a hemoglobin concentration above 9 g/dL if member had a baseline hemoglobin level above 7 g/dL but below 9 g/dL
- ☐ Member had a reduction in thrombotic events (e.g., DVT, PE)

EXCLUSIONS. Therapy will **NOT** be approved if member has history of any of the following:

- Unresolved meningococcal disease
- Any systemic bacterial or significant infections that have not been treated with appropriate antibiotics

Medication being provided by: Please check applicable box below.

- ☐ Location/site of drug administration: _____
 NPI or DEA # of administering location: _____
OR
- ☐ Specialty Pharmacy

For urgent reviews: Practitioner should call Sentara Health Plans Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health Plan's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****